Project Grant HT94252410928
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$565K
Federal Agency
Defense Health Agency
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
Mayo Clinic was awarded a $8,966,819 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from July 1, 2023 to June 30, 2027 to further develop purified exosome products for treating pulmonary damage from toxic exposures, leveraging Mayo Clinic's expertise in exosome applications. Through this funding, Mayo Clinic aims to advance biomedical solutions applicable to both military and civilian...
The federal Project Grant award of $1,782,155.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Mayo Clinic to identify novel drug targets for lethal prostate cancer using liquid biopsy. The award, effective from April 1, 2025, to March 31, 2028, will enable Mayo Clinic to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public. This...
The federal Project Grant award of $161,400.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research project titled "AN ATLAS OF THE TUMOR IMMUNE CIRCULOME." This award, with a performance period from June 1, 2024 to May 31, 2025, aims to advance medical knowledge and improve patient care through innovative biomedical research. The Military Medical Research and Development program funds a wide range of...
The Mayo Clinic was awarded a $1,605,726.00 Cooperative Agreement from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to provide treatment of pulmonary insults from acute and chronic toxic exposures using purified exosome products. The project aims to investigate medical solutions for the battlefield through innovative and impactful research focused on transforming health care for Service Members and the American public. The 3-year project...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
Mayo Clinic will receive $795,000 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct the project "PHARMACODYNAMIC BIOMARKER-GUIDED METABOLIC COLLAPSE OF IDH-MUTANT GLIOMA" from September 2021 through September 2024. This Project Grant aims to develop medical solutions for the battlefield by investigating pharmacodynamic biomarkers to guide targeted metabolic therapies for the treatment of isocitrate...
This $932,498 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to develop a non-invasive central nervous system (CNS) delivery method for immunocytokines to expand regulatory T cells (Tregs) and treat amyotrophic lateral sclerosis (ALS). The award recipient, the Regents of the University of Michigan, will leverage its expertise in biomedical research to conduct this cutting-edge...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
This federal Project Grant award, valued at $808,141.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award aims to advance research targeting inflammatory pathways in breast cancer brain metastases, with the goal of treating edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. The grant recipient is the Weill Medical College of Cornell University, a prominent academic medical institution with...